| Revenue growth | -10% YoY consolidated; exports volume down 8%. |
|---|---|
| Margins | EBITDA margin at 22% vs 27% YoY; gross margins impacted. |
| Order book | Continues to support growth outlook for new products. |
| Demand visibility | Soft global agrochemical demand; domestic volume up 12%. |
| Management confidence | Long-term outlook remains intact despite current cyclical headwinds. |
Growth
Exports revenue declined 13.3% YoY on soft global demand; domestic revenue grew 2.8% with biologicals up 50%+
Outlook
Launching 5+ new products in FY27; ₹2,685 Mn capex in Q1; net cash balance increased to ₹37,939 Mn.
Risks
Pricing pressure from generics, delayed monsoon impacting Kharif sowing, and geopolitical tensions increasing input material costs.
Last quarter's promises, checked
Delivered
- Guided 25% EBITDA margin for FY26 → delivered 25% (= BEAT)
- Guided sequential revenue growth for Q4 FY26 → delivered Rs. 15,652 Mn (= BEAT)
- Guided Pharma growth → delivered 40% growth for full year (= BEAT)
Partly delivered
- Guided ETR for FY26 at 22% → delivered 22% (but warned of 24% future rise) (= PARTIAL)
Missed
- Guided positive growth for FY27 → delivered -10% revenue in Q1 FY27 (= MISS)
- Guided EBITDA margin profile → delivered 22% in Q1 FY27 vs 25% FY26 commitment (= MISS)
Investor Presentation filed with BSE, NSE: PIIND. Summary written with AI assistance from the document.
PI Industries Ltd: key numbers
- Share price
- ₹2,400.00
- Market cap
- ₹36,412 Cr
- Revenue (annual)
- ₹6,714 Cr
- Net profit (annual)
- ₹1,321 Cr
- P/E (TTM)
- 31.3×Sector 37.5×
- Promoter holding
- 46.09%+0.00% QoQ
- FII holding
- 14.83%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from PI Industries Ltd
All →PI Industries Other Announcement
Bhavina J Dholariya, an immediate relative of an insider, sold equity shares of PI Industries Ltd. The market sale was valued at ₹0.12 Crore.
- Value
- ₹0.12 Cr
PI Industries Product Launch
PI Industries received registration for its indigenously developed insecticide, 'Pioxaniliprole' (branded 'Pioxazon'), marking a key milestone in its agricultural innovation journey.
PI Industries Earnings Call Transcript: Key Takeaways
PI Industries Q1 FY27 results show resilience amidst global agrochemical headwinds, maintaining healthy EBITDA margins at 22% despite revenue softness. Management remains optimistic about a second-half recovery driven by domestic monsoon improvement and new product scale-ups.
- Call
- Guides 5% growth
PI Industries Q1 FY27 Results: Net Profit ₹244.2 Cr, Down 39.0% YoY
PI Industries Ltd reported revenue from operations of ₹1,702 Cr (-10.4% YoY) and net profit of ₹244.2 Cr (-39.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹244.2 Cr · -39.0% YoY
PI Industries Earnings Call: Key Takeaways
PI Industries delivered FY26 revenue of ₹67,137M with 25% EBITDA margins. Management transitioned to an innovator-led model with the launch of its first homegrown NCE, Pioxaniliprole.
PI Industries Earnings Call: Key Takeaways
PI Industries delivered a resilient FY26 despite a global agrochemical downcycle. Management is pivoting toward life sciences and electronic chemicals to de-risk from their single-molecule dependency and agrochemical volatility.